Insmed (NASDAQ:INSM) Price Target Cut to $109.00 by Analysts at UBS Group
Insmed (NASDAQ:INSM – Free Report) had its target price reduced by UBS Group from $110.00 to $109.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other equities analysts have also recently issued research reports about the stock. Truist Financial lifted their target price […]
Insmed (NASDAQ:INSM – Free Report) had its target price reduced by UBS Group from $110.00 to $109.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other equities analysts have also recently issued research reports about the stock. Truist Financial lifted their target price […]
